The Korean Journal of Medicine

  • 제86권5호
  • /
  • Pages.537-545
  • /
  • 2014
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

인공호흡기 연관 폐렴의 예방과 치료

Prevention and Management of Ventilator-Associated Pneumonia

  • 박승용 (전북대학교 의과대학 내과학교실, 임상의학연구소) ;
  • 이흥범 (전북대학교 의과대학 내과학교실, 임상의학연구소)
  • Park, Seung Yong (Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School) ;
  • Lee, Heung Bum (Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School)
  • 발행 : 2014.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

Mechanical ventilation is currently an indispensable element within a hospital's intensive care unit (ICU). Regrettably, mechanical ventilation is also strongly associated with the risk of contracting ventilator-associated pneumonia (VAP), which is one of the most common causes of mortality and morbidity within the ICU, and has been for many years. The incidence of VAP has decreased in the last 10 years, from 14 to 9-10 cases per 1,000 days of mechanical ventilation. This has been an important achievement; however, hospital-acquired pneumonia and VAP still carry very high rates of morbidity and mortality, not to mention high financial costs as well. This comprehensive review explores our current understanding of the etiology and pathogenesis of VAP and proposes a strategy for its treatment and prevention.

키워드

참고문헌

  1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903. https://doi.org/10.1164/ajrccm.165.7.2105078
  2. Fagon JY, Chastre J, Hance AJ, et al. Detection of nosocomial lung infection in ventilated patients: use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis 1988;138:110-116. https://doi.org/10.1164/ajrccm/138.1.110
  3. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43(Suppl 2):S43-48. https://doi.org/10.1086/504476
  4. Craven DE, Kunches LM, Kilinsky V, Lichtenberg DA, Make BJ, McCabe WR. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1986;133:792-796.
  5. Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med 2004;32:1396-1405. https://doi.org/10.1097/01.CCM.0000128569.09113.FB
  6. Shorr AF, Sherner JH, Jackson WL, Kollef MH. Invasive approaches to the diagnosis of ventilator-associated pneumonia: a meta-analysis. Crit Care Med 2005;33:46-53. https://doi.org/10.1097/01.CCM.0000149852.32599.31
  7. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006;355:2619-2630. https://doi.org/10.1056/NEJMoa052904
  8. Centers for Disease Control and Prevention (CDC). National Healthcare Safety Network. CDC Atlantan GA, [Internet]. CDC, c2014 [cited 2014 January 6], Available from: HYPERLINK www.cdc.gov/nhsn/PDFs/pscManual/6pscVAPcurrent.pdf.
  9. Klompas M. Does this patient have ventilator-associated pneumonia? JAMA 2007;297:1583-1593. https://doi.org/10.1001/jama.297.14.1583
  10. Schurink CA, Van Nieuwenhoven CA, Jacobs JA, et al. Clinical pulmonary infection score for ventilator-associated pneumonia: accuracy and inter-observer variability. Intensive Care Med 2004;30:217-224. https://doi.org/10.1007/s00134-003-2018-2
  11. Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin Infect Dis 2010;51(Suppl 1):S131-135. https://doi.org/10.1086/653062
  12. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416. https://doi.org/10.1164/rccm.200405-644ST
  13. Kollef MH. The prevention of ventilator-associated pneumonia. N Engl J Med 1999;340:627-634. https://doi.org/10.1056/NEJM199902253400807
  14. Coffin SE, Klompas M, Classen D, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol 2008;29(Suppl 1):S31-40. https://doi.org/10.1086/591062
  15. Bonten MJ. Healthcare epidemiology: ventilator-associated pneumonia: preventing the inevitable. Clin Infect Dis 2011;52:115-121. https://doi.org/10.1093/cid/ciq075
  16. Torres A, Serra-Batlles J, Ros E, et al. Pulmonary aspiration of gastric contents in patients receiving mechanical ventilation: the effect of body position. Ann Intern Med 1992;116:540-543. https://doi.org/10.7326/0003-4819-116-7-540
  17. Orozco-Levi M, Torres A, Ferrer M, et al. Semirecumbent position protects from pulmonary aspiration but not completely from gastroesophageal reflux in mechanically ventilated patients. Am J Respir Crit Care Med 1995;152(4 Pt 1):1387-1390. https://doi.org/10.1164/ajrccm.152.4.7551400
  18. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999;354:1851-1858. https://doi.org/10.1016/S0140-6736(98)12251-1
  19. Muscedere J, Rewa O, McKechnie K, Jiang X, Laporta D, Heyland DK. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care Med 2011;39:1985-1991. https://doi.org/10.1097/CCM.0b013e318218a4d9
  20. Mentec H, Dupont H, Bocchetti M, Cani P, Ponche F, Bleichner G. Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Crit Care Med 2001;29:1955-1961. https://doi.org/10.1097/00003246-200110000-00018
  21. McClave SA, Lukan JK, Stefater JA, et al. Poor validity of residual volumes as a marker for risk of aspiration in critically ill patients. Crit Care Med 2005;33:324-330. https://doi.org/10.1097/01.CCM.0000153413.46627.3A
  22. Montejo JC, Minambres E, Bordeje L, et al. Gastric residual volume during enteral nutrition in ICU patients: the REGANE study. Intensive Care Med 2010;36:1386-1393. https://doi.org/10.1007/s00134-010-1856-y
  23. Heyland DK, Drover JW, Dhaliwal R, Greenwood J. Optimizing the benefits and minimizing the risks of enteral nutrition in the critically ill: role of small bowel feeding. JPEN J Parenter Enteral Nutr 2002;26(6 Suppl):S51-55. https://doi.org/10.1177/014860710202600608
  24. Reignier J, Mercier E, Le Gouge A, et al. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial. JAMA 2013;309:249-256. https://doi.org/10.1001/jama.2012.196377
  25. McClave SA, Lukan JK, Stefater JA, et al. Poor validity of residual volumes as a marker for risk of aspiration in critically ill patients. Crit Care Med 2005;33:324-330. https://doi.org/10.1097/01.CCM.0000153413.46627.3A
  26. Bouadma L, Wolff M, Lucet JC. Ventilator-associated pneumonia and its prevention. Curr Opin Infect Dis 25(4):395-404.
  27. Kollef MH, Afessa B, Anzueto A, et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA 2008;300:805-813. https://doi.org/10.1001/jama.300.7.805
  28. Roquilly A, Mahe PJ, Seguin P, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA 2011;305:1201-1209. https://doi.org/10.1001/jama.2011.360
  29. Berenholtz SM, Pham JC, Thompson DA, et al. Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. Infect Control Hosp Epidemiol 2011;32:305-314. https://doi.org/10.1086/658938
  30. Bouadma L, Deslandes E, Lolom I, et al. Long-term impact of a multifaceted prevention program on ventilator-associated pneumonia in a medical intensive care unit. Clin Infect Dis 2010;51:1115-1122. https://doi.org/10.1086/656737
  31. Kollef MH. Prevention of nosocomial pneumonia in the intensive care unit: beyond the use of bundles. Surg Infect (Larchmt) 2011;12:211-220. https://doi.org/10.1089/sur.2010.060
  32. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998;113:412-420. https://doi.org/10.1378/chest.113.2.412
  33. Leroy O, Meybeck A, d'Escrivan T, Devos P, Kipnis E, Georges H. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003;29:2170-2173. https://doi.org/10.1007/s00134-003-1990-x
  34. Teixeira PJ, Seligman R, Hertz FT, Cruz DB, Fachel JM. Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. J Hosp Infect 2007;65:361-367. https://doi.org/10.1016/j.jhin.2006.12.019
  35. Song JH; Asian Hospital Acquired Pneumonia Working Group. Treatment recommendations of hospital-acquired pneumonia in Asian countries: first consensus report by the Asian HAP Working Group. Am J Infect Control 2008;36(4 Suppl):S83-92. https://doi.org/10.1016/j.ajic.2007.01.015
  36. Kwak YG, Cho YK, Kim JY, et al. Korean nosocomial infections surveillance system, intensive care unit module report: data summary from July 2008 through June 2009 and analysis of 3-year results. Korean J Nosocomial Infect Control 2010;15:14-25.
  37. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-2598. https://doi.org/10.1001/jama.290.19.2588
  38. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001;29:1109-1115. https://doi.org/10.1097/00003246-200106000-00003
  39. Kalil AC, Klompas M, Haynatzki G, Rupp ME. Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis. BMJ Open 2013;3:e003912. https://doi.org/10.1136/bmjopen-2013-003912
  40. Walkey AJ, O'Donnell MR, Wiener RS. Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 2011;139:1148-1155. https://doi.org/10.1378/chest.10-1556
  41. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-327. https://doi.org/10.1086/600877
  42. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98. https://doi.org/10.2146/ajhp080434
  43. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012;54:621-629. https://doi.org/10.1093/cid/cir895
  44. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55. https://doi.org/10.1093/cid/ciq146
  45. Rubinstein E, Lalani T, Corey GR, et al. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 2011;52:31-40. https://doi.org/10.1093/cid/ciq031
  46. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin: Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000;161(3 Pt 1):753-762. https://doi.org/10.1164/ajrccm.161.3.9904115
  47. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010;51:1395-1405. https://doi.org/10.1086/657313
  48. US Food and Drug Administration (FDA). FDA drug safety communication: Risk When Used to Treat Pneumonia on Ventilated Patients [Internet] US Food and Drug Administration, c2013 [cited 2012 January 5]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm
  49. US Food and Drug Administration (FDA). FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new boxed warning [Internet]. US Food and Drug Administration, c2013 [cited 2013 Oct 9]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm369580.htm.
  50. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68:140-151. https://doi.org/10.1016/j.diagmicrobio.2010.05.012
  51. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012;54:1699-1709. https://doi.org/10.1093/cid/cis270
  52. Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008;36:108-117. https://doi.org/10.1097/01.CCM.0000297956.27474.9D
  53. Heyland DK, Dodek P, Muscedere J, Day A, Cook D; Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008;36:737-744. https://doi.org/10.1097/01.CCM.0B013E31816203D6
  54. US Food and Drug Administration. FDA approves label changes for antibacterial Doribax (doripenem) describing increased risk of death for ventilator patients with pneumonia [Internet]. US Food and Drug Administration, c2014 [cited 2014 Mar 10]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm387971.htm.

피인용 문헌

  1. 가정용 인공호흡기 적용 신경근육계 희귀난치성 질환자 가족 간호제공자의 기관내 흡인 수행과 폐렴 발생과의 관계 vol.23, pp.1, 2014, https://doi.org/10.22705/jkashcn.2016.23.1.025
  2. 신경근육질환으로 인한 호흡곤란을 호소하는 소음인환자 치험 1례 보고 vol.28, pp.4, 2014, https://doi.org/10.7730/jscm.2016.28.4.403
  3. 중증 외상환자의 인공호흡기 관련 폐렴 영향 요인 분석 vol.25, pp.3, 2018, https://doi.org/10.22705/jkashcn.2018.25.3.224
  4. The Distribution of Multidrug-resistant Microorganisms and Treatment Status of Hospital-acquired Pneumonia/Ventilator-associated Pneumonia in Adult Intensive Care Units: a Prospective Cohort Observati vol.36, pp.41, 2021, https://doi.org/10.3346/jkms.2021.36.e251
  5. Development of a competency for professional oral hygiene care of endotracheally-intubated patients in the intensive care unit: development and validity evidence vol.21, pp.1, 2014, https://doi.org/10.1186/s12913-021-06755-z